NEW YORK–(BUSINESS WIRE)–Viscogliosi Bros., LLC (VB), a merchant banking and venture capital/private equity firm focused exclusively on the musculoskeletal/orthopedics sector, today reported it acted as strategic advisor to Olympus Corporation for its $60 million purchase of Stryker Corporation’s OP-1 bone product family, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft.
Anthony G. Viscogliosi, a Principal at VB, said: “We are extremely pleased to have had the opportunity to advise Olympus Corporation on this transaction. We believe that the combination of Olympus’ existing biomaterial and regenerative medicine technologies and OP-1 bone products will allow Olympus to achieve a leadership position in regenerative medicine globally. We look forward to continuing to advise the Olympus team and unlocking the potential we all see in the OP-1 bone product family.”
About Viscogliosi Brothers, LLC.
Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in New York City in 1999, Viscogliosi Bros., LLC (VB) was the first merchant banking and venture capital/private equity firm dedicated exclusively to the musculoskeletal/orthopedics sector of the health care industry.
VB’s mission is to create, build and finance companies founded on innovations developed by surgeons and uniquely focused on “life changing” musculoskeletal/orthopedic technologies. Marc, Anthony and John Viscogliosi have executed multiple financial, strategic and management transactions for companies in the musculoskeletal/orthopedic sector.
For more information on VB, please visit: www.vbllc.com